A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (GS-4059) and Idelalisib With and Without Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2017
At a glance
- Drugs Idelalisib (Primary) ; Obinutuzumab (Primary) ; Tirabrutinib (Primary)
- Indications Lymphoid leukaemia
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 09 Nov 2017 Planned End Date changed from 1 Oct 2022 to 1 Aug 2023.
- 09 Nov 2017 Planned primary completion date changed from 1 Jan 2019 to 1 Feb 2019.
- 24 Aug 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jan 2019.